Lipid metabolites as potential diagnostic and prognostic biomarkers for acute community acquired pneumonia

Early diagnosis of acute community-acquired pneumonia (CAP) is important in patient triage and treatment decisions. To identify biomarkers that distinguish patients with CAP from non-CAP controls, we conducted an untargeted global metabolome analysis for plasma samples from 142 patients with CAP (CA...

Descripción completa

Detalles Bibliográficos
Autores principales: To, Kelvin K.W., Lee, Kim-Chung, Wong, Samson S.Y., Sze, Kong-Hung, Ke, Yi-Hong, Lui, Yin-Ming, Tang, Bone S.F., Li, Iris W.S., Lau, Susanna K.P., Hung, Ivan F.N., Law, Chun-Yiu, Lam, Ching-Wan, Yuen, Kwok-Yung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Inc. 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7173326/
https://www.ncbi.nlm.nih.gov/pubmed/27105773
http://dx.doi.org/10.1016/j.diagmicrobio.2016.03.012
Descripción
Sumario:Early diagnosis of acute community-acquired pneumonia (CAP) is important in patient triage and treatment decisions. To identify biomarkers that distinguish patients with CAP from non-CAP controls, we conducted an untargeted global metabolome analysis for plasma samples from 142 patients with CAP (CAP cases) and 97 without CAP (non-CAP controls). Thirteen lipid metabolites could discriminate between CAP cases and non-CAP controls with area-under-the-receiver-operating-characteristic curve of >0.8 (P ≤ 10(−9)). The levels of glycosphingolipids, sphingomyelins, lysophosphatidylcholines and L-palmitoylcarnitine were higher, while the levels of lysophosphatidylethanolamines were lower in the CAP cases than those in non-CAP controls. All 13 metabolites could distinguish CAP cases from the non-infection, extrapulmonary infection and non-CAP respiratory tract infection subgroups. The levels of trihexosylceramide (d18:1/16:0) were higher, while the levels of lysophosphatidylethanolamines were lower, in the fatal than those of non-fatal CAP cases. Our findings suggest that lipid metabolites are potential diagnostic and prognostic biomarkers for CAP.